Prediction of the product line under research of top 10 pharmaceutical plants in 2017

Source: Sina Pharmaceutical News 2016-12-30 2015 pharmexec website "global TOP10 prescription drug ranking revenue" collated the global pharmaceutical enterprise revenue in 2016, and 2017 related forecast and product line analysis, for readers' reference! 1 Pfizer Pfizer in recent years has been a reversal of the declining sales volume for Pfizer The sales growth in the post Lipitor era is weak Through independent R & D and external acquisition, the sales volume is expected to grow rapidly since 2016 This year's major sales growth came from ibrance (palbociclib), eliquis (edoxaban), xeljanz (tofatinib), Lyrica (pregabalin) and Chantix (Changpei) Since the failure of acquisition of Elgin in 2015, Pfizer has never stopped the pace of acquisition, and has successively acquired hospitra pharmaceutical to strengthen its injection generic product line and biological similar drug research product line (this year, infliximab biological similar drug was first approved by FDA for listing) This year, another US $14.3 billion acquisition of the prostate cancer drug xtandi (enzalutamide) by medivation made the anti-tumor drug an extra blockbuster At present, other indications of the inhibitor are still under development, and talazoparib, a better PARP inhibitor, has been obtained, which complements its leading position in the small molecule market of breast cancer After that, it acquired bambootherapeutics, a rare disease company of gene therapy, for us $645 million, which is also in layout for emerging fields The acquisition of ANACOR pharmaceutical for us $5.2 billion brings 2% cream for eczema medication, crisaborole, with an estimated annual sales volume of US $2 billion Original details: http://news.bioon.com/article/6696464.html